<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16</volume><submitter>Deserranno K</submitter><pubmed_abstract>Clinical pharmacogenomics (PGx) testing strategies are mainly based on targeted PCR, microarrays, or short-read sequencing. These methods perform well for detecting known single-nucleotide variants (SNVs), small insertions/deletions (indels), and certain copy number variants (CNVs), but they fall short in resolving complex structural variants (SVs), particularly in complex pharmacogenes such as &lt;i>CYP2D6&lt;/i>. Therefore, we previously developed a targeted PGx test based on long-read Oxford Nanopore Technologies (ONT) sequencing. Harnessing adaptive sampling (AS) for &lt;i>in silico&lt;/i> enrichment of a panel of PGx genes, we illustrated superior performance in star-allele calling compared to the Genetic Testing Reference Materials Program (GeT-RM) truth set. However, accurate diplotyping of &lt;i></pubmed_abstract><journal>Frontiers in pharmacology</journal><pagination>1653999</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12455207</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Comparative evaluation of Oxford Nanopore Technologies' adaptive sampling and the Twist long-read PGx panel for pharmacogenomic profiling.</pubmed_title><pmcid>PMC12455207</pmcid><pubmed_authors>Deserranno K</pubmed_authors><pubmed_authors>Deforce D</pubmed_authors><pubmed_authors>Tilleman L</pubmed_authors><pubmed_authors>Van Nieuwerburgh F</pubmed_authors></additional><is_claimable>false</is_claimable><name>Comparative evaluation of Oxford Nanopore Technologies' adaptive sampling and the Twist long-read PGx panel for pharmacogenomic profiling.</name><description>Clinical pharmacogenomics (PGx) testing strategies are mainly based on targeted PCR, microarrays, or short-read sequencing. These methods perform well for detecting known single-nucleotide variants (SNVs), small insertions/deletions (indels), and certain copy number variants (CNVs), but they fall short in resolving complex structural variants (SVs), particularly in complex pharmacogenes such as &lt;i>CYP2D6&lt;/i>. Therefore, we previously developed a targeted PGx test based on long-read Oxford Nanopore Technologies (ONT) sequencing. Harnessing adaptive sampling (AS) for &lt;i>in silico&lt;/i> enrichment of a panel of PGx genes, we illustrated superior performance in star-allele calling compared to the Genetic Testing Reference Materials Program (GeT-RM) truth set. However, accurate diplotyping of &lt;i></description><dates><release>2025-01-01T00:00:00Z</release><publication>2025</publication><modification>2026-06-03T19:41:21.064Z</modification><creation>2026-05-01T03:10:32.122Z</creation></dates><accession>S-EPMC12455207</accession><cross_references><pubmed>40994639</pubmed><doi>10.3389/fphar.2025.1653999</doi></cross_references></HashMap>